Business
HYTN Announces Proposed Spin-Out of BPC-157 Peptide Drug Development Business
VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) ("HYTN" or the "Company") announces that its Board of Directors has approved the spin-out of an internally developed peptide drug development business into a dedicated new company ("SpinCo"). As part of the proposed spin-out, SpinCo is expected to complete a concurrent financing to fund the next phase of its development and to pursue a public listing on the Canadian Sec
About this update from Hytn Innovations Inc
[{"type":"image","alt":"HYTN Innovations Inc.","displaySize":"","headline":null,"caption":"HYTN Innovations Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":267,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/d0d2c55d487605e813bedcd12be5d8b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WwJCiVlVdiZV0YtQRlnsrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/d0d2c55d487605e813bedcd12be5d8b1","width":267,"height":91}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) ("HYTN" or the "Company") announces that its Board of Directors has approved the spin-out of an internally developed peptide drug development business into a dedicated new company ("SpinCo"). As part of the proposed spin-out, SpinCo is expected to complete a concurrent financing to fund the next phase of its development and to pursue a public listing on the Canadian Securities Exchange (the "CSE"), subject to regulatory approvals and market conditions.","length":624,"tagName":"p"},{"type":"text","content":"The proposed spin-out is intended to separate from HYTN a peptide-focused drug development business centered on the pre-clinical development of a subcutaneous injectable BPC-157 drug candidate for refractory ligament disorders. HYTN has built this business internally and has assembled the manufacturing, operating, regulatory and quality framework required to advance the program into the next stage of clinical development.","length":425,"tagName":"p"},{"type":"text","content":"The business proposed to be transferred to SpinCo includes the assets, Good Manufacturing Practices ("GMP") operating systems, regulatory framework and related know-how comprising HYTN’s peptide drug development business, together with the documentation, clinical-support processes and infrastructure required to advance the program.","length":343,"tagName":"p"},{"type":"text","content":"HYTN has selected a Canadian GMP-certified sterile pharmaceutical contract manufacturing organization for the initial manufacture of sterile BPC-157 drug product and has selected an approved medical device platform intended to support dose-controlled subcutaneous administration. HYTN h...